Immune checkpoint inhibitors (ICIs) are immunotherapy drugs that mobilize the patient’s immune system to detect and attack cancer cells. They are considered a breakthrough development in cancer care, ...

The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell ...

Adding a minimally invasive laser procedure to immunotherapy achieved dramatically improved survival in a small study of patients with recurrent high-grade astrocytoma, an aggressive brain cancer with ...

Fecal microbiota transplants may enhance patients’ response to immunotherapy, but experts caution that the latest data remain proof-of-concept and far from practice-changing.

Soheil Meshinchi, MD, PhD, a world leader in developing novel approaches to treating acute myeloid leukemia (AML), has been ...

Phase II data suggest fewer GI adverse effects when given a sequence of biologics ...

Nigeria on Wednesday launched its first clinical trial using immunotherapy to treat colorectal cancer, a move doctors say ...

The global oncology market is projected to nearly triple from $279.98 billion in 2026 to an estimated $748.17 billion by 2035 ...

In Perioperative Immunotherapy Advances: Insights from CheckMate-77T and KEYNOTE-671, our panel delves into the following ...

Find out how immunotherapy can improve cancer treatment outcomes and the systemic barriers limiting its widespread use.

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally ...

Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...